Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · AbbVie (ABBV)

AbbVie Reports Third-Quarter 2026 Results and Raises Full-Year Guidance

Positive Impact 4 of 5 earnings

AbbVie announced third-quarter 2026 net revenues of $17.404 billion and diluted EPS of $2.37 on a GAAP basis. The company raised its full-year 2026 adjusted diluted EPS guidance range to $13.95 through $13.99 and increased its quarterly cash dividend by 5.2 percent to $1.82 per share.

Key points

  • Third-quarter net revenues reached $17.404 billion, representing a 10.3 percent increase on a reported basis.
  • GAAP diluted EPS was $2.37, while adjusted diluted EPS was $3.82 for the third quarter ended September 30, 2026.
  • Full-year 2026 adjusted diluted EPS guidance was raised to a range of $13.95 to $13.99.
  • The quarterly cash dividend was increased by 5.2 percent to $1.82 per share, payable on February 16, 2027.

The filing

CompanyAbbVie (ABBV)
Form8-K, current report
Filed with the SECOct 30, 2026, 7:51 AM ET
Accession number0001551152-26-000033

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Oct 30, 2026, 8:17 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.